AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19222545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (PGB)
Number of subjects: 178
Study 19222545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 178
Study 16862612 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP laparoscopic patch repair
Number of subjects: 1513
Study 16862612 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein mesh technique
Number of subjects: 1513
Study 15476991 — intervention group
Group type: EXPERIMENTAL
Intervention: Community rehabilitation service (CRN) including orientation meeting, self-help course, stress management program, water exercises class, informal social and recreational activities.
Number of subjects: 29
Study 15476991 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention details provided).
Number of subjects: 29
Study 10679609 — intervention group
Group type: EXPERIMENTAL
Intervention: Life albums created by residents
Number of subjects: 13
Study 10165553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement patch (Prostep, Lederle Laboratories) with no additional support (Group I, n = 166)
Number of subjects: 509
Study 10165553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support (Group II, n = 167)
Number of subjects: 509
Study 10165553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support and four follow-up calls (Group III, n = 167)
Number of subjects: 509
Study 10165553 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group not explicitly defined)
Number of subjects: 509
Study 8475816 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg fusidic acid (intervention)
Number of subjects: 90
Study 8475816 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 90
Study 3823635 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 10
Study 3823635 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of prednisolone
Number of subjects: 10
Study 30661105 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD alone (400 mg)
Number of subjects: 36
Study 30661105 — intervention group
Group type: EXPERIMENTAL
Intervention: THC alone (8 mg)
Number of subjects: 36
Study 30661105 — intervention group
Group type: EXPERIMENTAL
Intervention: THC combined with low dose CBD (4 mg)
Number of subjects: 36
Study 30661105 — intervention group
Group type: EXPERIMENTAL
Intervention: THC combined with high dose CBD (400 mg)
Number of subjects: 36
Study 30661105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29110150 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min, vigorous-intensity treadmill bout 24 hours prior to each of four doxorubicin treatments
Number of subjects: 24
Study 29110150 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 26872808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D presentation mode
Number of subjects: 410
Study 26872808 — intervention group
Group type: COMPARATOR
Intervention: 2D presentation mode
Number of subjects: 410
Study 26872808 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Men vs Women)
Number of subjects: 410
Study 26872808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun factor
Number of subjects: 410
Study 26872808 — intervention group
Group type: COMPARATOR
Intervention: Preference for presentation mode
Number of subjects: 410
Study 24633502 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed (18)FDG PET/CT imaging at 180 minutes
Number of subjects: 40
Study 24633502 — intervention group
Group type: COMPARATOR
Intervention: (18)FDG PET/CT imaging at 90 minutes
Number of subjects: 40
Study 22538083 — intervention group
Group type: EXPERIMENTAL
Intervention: special carbohydrate-protein cake (carbohydrate to whey protein 3.5:1)
Number of subjects: 9
Study 22538083 — intervention group
Group type: COMPARATOR
Intervention: isocaloric carbohydrate cake
Number of subjects: 9
Study 20359643 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Adjustable Warming System (Bair PAWS)
Number of subjects: 130
Study 20359643 — intervention group
Group type: COMPARATOR
Intervention: Warm Blanket
Number of subjects: 130
Study 19226891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and conventional rehabilitation therapy
Number of subjects: 69
Study 19226891 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (Control)
Number of subjects: 69
Study 16253059 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiVu HD3 Heads‐Up goggles
Number of subjects: 12
Study 16253059 — intervention group
Group type: COMPARATOR
Intervention: 20-inch Sony Triniton monitor (TV)
Number of subjects: 12
Study 11919119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken-based diet
Number of subjects: 28
Study 11919119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 28
Study 10232685 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued ramipril (1.25 to 5 mg/d)
Number of subjects: 150
Study 10232685 — intervention group
Group type: COMPARATOR
Intervention: Switched to ramipril
Number of subjects: 150
Study 10232685 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued ramipril (with at least six GFR measurements)
Number of subjects: 150
Study 10232685 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued ramipril
Number of subjects: 150
Study 8975262 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal Characteristic of Behaviour‐Temperamental Questionnaire (FCZ‐KT)
Number of subjects: 60
Study 8975262 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiener‐Testsystem (WT)
Number of subjects: 60
Study 1769930 — intervention group
Group type: EXPERIMENTAL
Intervention: aztreonam plus flucloxacillin
Number of subjects: 100
Study 1769930 — intervention group
Group type: COMPARATOR
Intervention: piperacillin plus gentamicin
Number of subjects: 100
Study 6287359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 0
Study 6287359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6287359 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (single IV infusion)
Number of subjects: 0
Study 29908832 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-guided LV lead placement
Number of subjects: 99
Study 29908832 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiologically guided LV lead placement (EP group)
Number of subjects: 99
Study 28733869 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual or biennial screening by fecal occult blood testing
Number of subjects: 46551
Study 28733869 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 46551
Study 25444352 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS toric IOL (ZCT150)
Number of subjects: 265
Study 25444352 — intervention group
Group type: COMPARATOR
Intervention: TECNIS 1-piece control IOL (ZCB00)
Number of subjects: 265
Study 25444352 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label arm (ZCT225, ZCT300, ZCT400)
Number of subjects: 265
Study 23639793 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 23639793 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic trials with adequate allocation concealment, double blinding, higher precision, larger trial size, at least three treatment arms, recent publication, conducted in the United States, and enrollment of inpatients
Number of subjects: 0
Study 23639793 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 21317283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg daily (titrated to 30 and 60 mg if necessary)
Number of subjects: 110
Study 21317283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18574016 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-based clinical pharmacists in the ICU (full-time)
Number of subjects: 3
Study 18574016 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-based clinical pharmacists in general care units (part-time)
Number of subjects: 3
Study 18574016 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar patient care units without unit-based clinical pharmacists)
Number of subjects: 3
Study 16934685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 125 mg daily
Number of subjects: 233
Study 16934685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 500 mg weekly
Number of subjects: 233
Study 16934685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 12220946 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol (24 microg dry powder)
Number of subjects: 24
Study 12220946 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol
Number of subjects: 24
Study 12220946 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 9457093 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (11 mL, between 11(+0) and 12(+6) gestational weeks)
Number of subjects: 4374
Study 9457093 — intervention group
Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (20 mL, between 15(+0) and 16(+6) gestational weeks)
Number of subjects: 4374
Study 9457093 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 4374
Study 9457093 — intervention group
Group type: COMPARATOR
Intervention: Midtrimester amniocentesis
Number of subjects: 4374
Study 8572639 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A: 1 mg of GRAN initially and 12 hours after the first dose
Number of subjects: 30
Study 8572639 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B: a single 2 mg dose of GRAN
Number of subjects: 30
Study 8572639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study 2404435 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM clinical intervention administered in the ED
Number of subjects: 139
Study 2404435 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM telephone intervention two to four days after the ED visit
Number of subjects: 139
Study 2404435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HBM clinical and telephone interventions
Number of subjects: 139
Study 2404435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 139
Study 1023957 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 250 mg in dextrose 5%
Number of subjects: 0
Study 1023957 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 5% alone
Number of subjects: 0
Study 7240103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapy information provided via a printed leaflet included with the application blank for alternate cases.
Number of subjects: 1300
Study 7240103 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who participated in psychotherapy after receiving pretherapy information.
Number of subjects: 1300
Study 7240103 — intervention group
Group type: COMPARATOR
Intervention: Patients with health insurance.
Number of subjects: 1300
Study 31907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSA group
Number of subjects: 83
Study 31907125 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 31907125 — intervention group
Group type: EXPERIMENTAL
Intervention: All OSA groups
Number of subjects: 83
Study 31907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 83
Study 31907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise multiple regression analysis
Number of subjects: 83
Study 31907125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tt.vBMD of radius
Number of subjects: 83
Study 29290494 — intervention group
Group type: EXPERIMENTAL
Intervention: High/immeasurable ABI
Number of subjects: 260
Study 29290494 — intervention group
Group type: COMPARATOR
Intervention: Intermediate ABI
Number of subjects: 260
Study 29290494 — intervention group
Group type: COMPARATOR
Intervention: Low ABI
Number of subjects: 260
Study 26631085 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral self-regulation intervention
Number of subjects: 119
Study 26631085 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (attention-placebo support and discussion)
Number of subjects: 119
Study 24968814 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 24968814 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 90
Study 24968814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 90
Study 22864190 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement program
Number of subjects: 5912
Study 22864190 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 5912
Study 20849938 — intervention group
Group type: EXPERIMENTAL
Intervention: BGP-15 (400mg once daily for 17 days)
Number of subjects: 37
Study 20849938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 37
Study 18179312 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually-impoverished environment training under alcohol (0.65 g/kg)
Number of subjects: 30
Study 18179312 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal visual environment training under alcohol (0.65 g/kg)
Number of subjects: 30
Study 18179312 — intervention group
Group type: COMPARATOR
Intervention: Control group trained and tested under visually-impoverished condition
Number of subjects: 30
Study 15766377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pointed-shaped brush head (PBH)
Number of subjects: 40
Study 15766377 — intervention group
Group type: COMPARATOR
Intervention: Standard cup-shaped brush head (CBH)
Number of subjects: 40
Study 12396317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus chlorpheniramine (CQCP)
Number of subjects: 131
Study 12396317 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 131
Study 12396317 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 131
Study 10682110 — intervention group
Group type: EXPERIMENTAL
Intervention: GDP-free PD solution
Number of subjects: 31
Study 10682110 — intervention group
Group type: COMPARATOR
Intervention: Conventional PD solution
Number of subjects: 31
Study 8646568 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus fragrance
Number of subjects: 12
Study 2283647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg (10 patients) and 20 mg (2 patients) twice daily for 8 weeks
Number of subjects: 12
Study 218427 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 218427 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 218427 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 0
Study 218427 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 31010372 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity acute exercise
Number of subjects: 22
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of pre-made healthy family meals
Number of subjects: 512
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of healthy meal ingredients
Number of subjects: 512
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Community kitchens for parents to make healthy meals
Number of subjects: 512
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating classes
Number of subjects: 512
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking demonstrations
Number of subjects: 512
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cookware/flatware delivery
Number of subjects: 512
Study 28187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled intervention (to be determined)
Number of subjects: 512
Study 28187722 — intervention group
Group type: COMPARATOR
Intervention: Usual Head Start Exposure
Number of subjects: 512
Study 24523431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management (individualized follow-up programme with home visits and telephone calls for 1 year)
Number of subjects: 329
Study 24523431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management
Number of subjects: 329
Study 24523431 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 329
Study 23896377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant PCV (Procarbazine, CCNU, Vincristine) chemotherapy
Number of subjects: 368
Study 21853760 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-centered program on sport nutrition, exercise, and disordered eating consequences (4 weeks)
Number of subjects: 40
Study 21853760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 18534415 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface replacement arthroplasty
Number of subjects: 200
Study 18534415 — intervention group
Group type: COMPARATOR
Intervention: Total hip arthroplasty
Number of subjects: 200
Study 17675341 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma stored at 4, 21, or 30 degrees C for 1-5 days
Number of subjects: 10
Study 17675341 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood stored at 4, 21, or 30 degrees C for 1-5 days
Number of subjects: 10
Study 17675341 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 freeze-thaw cycles
Number of subjects: 10
Study 17675341 — intervention group
Group type: COMPARATOR
Intervention: Immediate assay
Number of subjects: 10
Study 15151167 — intervention group
Group type: EXPERIMENTAL
Intervention: Zobo drink (Hibiscus sabdariffa water extract)
Number of subjects: 6
Study 15151167 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1g) administered after zobo drink
Number of subjects: 6
Study 15151167 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1g) administered alone
Number of subjects: 6
Study 12202092 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 13
Study 12202092 — intervention group
Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 13
Study 9832115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lisinopril-isosorbide dinitrate therapy
Number of subjects: 0
Study 9832115 — intervention group
Group type: COMPARATOR
Intervention: Established doses of angiotensin-converting enzyme inhibitor and nitrate therapy
Number of subjects: 0
Study 8607311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microgram.kg‐1.min‐1, n = 12)
Number of subjects: 35
Study 8607311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2.5 micrograms.kg‐1.min‐1, n = 11)
Number of subjects: 35
Study 8607311 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 35
Study 2561096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (O‐GTT)
Number of subjects: 0
Study 2561096 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Secretion Test (IST)
Number of subjects: 0
Study 2561096 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta IST/delta O‐GTT
Number of subjects: 0
Study 1258516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 28
Study 1258516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyfedrin
Number of subjects: 28
Study 31984598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 12 mg
Number of subjects: 111
Study 31984598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg-1
Number of subjects: 111
Study 31984598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg-2
Number of subjects: 111
Study 31984598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 29601789 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF) membrane
Number of subjects: 30
Study 29601789 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane
Number of subjects: 30
Study 27991604 — intervention group
Group type: EXPERIMENTAL
Intervention: Wall Climbing Intervention (WCI)
Number of subjects: 35
Study 27991604 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 35
Study 25703320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (10 sessions + 2 booster sessions)
Number of subjects: 1176
Study 23262999 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9851 (25 to 800 mg)
Number of subjects: 0
Study 23262999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21636183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral essential amino acids 4 gr 2 times a day for 8 weeks
Number of subjects: 41
Study 21636183 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 41
Study 18175066 — intervention group
Group type: EXPERIMENTAL
Intervention: E+L+ (10 + 50 mg/day)
Number of subjects: 64
Study 18175066 — intervention group
Group type: EXPERIMENTAL
Intervention: L+ (50 mg/day)
Number of subjects: 64
Study 18175066 — intervention group
Group type: EXPERIMENTAL
Intervention: TT genotype of AGT
Number of subjects: 64
Study 18175066 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA
Number of subjects: 64
Study 17205814 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenle Capsule (SC)
Number of subjects: 70
Study 17205814 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril
Number of subjects: 70
Study 14638484 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg)
Number of subjects: 12
Study 14638484 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 12
Study 11012490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 38
Study 11012490 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 38
Study 9046509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute arthroscopic lavage within 10 days
Number of subjects: 30
Study 9046509 — intervention group
Group type: COMPARATOR
Intervention: Traditional non-operative therapy
Number of subjects: 30
Study 9046509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute MRI
Number of subjects: 30